Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.
Rebecca Bigler, PhD
Advertisement
Articles by Rebecca Bigler, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
Dosing, Monitoring, and Counseling: The Pharmacist's Role in TKI Therapy for Systemic Mastocytosis
4
What Pharmacists Should Know About the Ifosfamide Shortage
5